Although blood-based protein biomarkers are already utilized in clinical settings, including P53, isocitrate dehydrogenase 1 and Bcl-2, they cannot be used alone to screen or diagnose cancer as the levels of these markers can be abnormal for reasons other than cancer [22]. This evidence concerns the gene TP53 and cancer.